A Simple, Easy & Attractive Buy:

Simply sign up for the FREE Cabot Wealth Advisory and we'll immediately give you this latest research report ... absolutely FREE:

My Favorite ETF for 2012

With all the volatility individual stocks have seen lately, you may be looking for an alternative investment. We suggest exchange-traded funds (ETFs), which are investment funds that are traded on stock exchanges. ETFs hold assets like stocks, commodities or bonds, making them less risky than most individual stocks. This report contains our favorite ETF for 2012. It's an ETF that has shown to be a steady performer in the past six months, while the stock market has produced not much more than extreme volatility.

The Cabot Wealth Advisory e-letter delivers independent, no-nonsense investment advice, focusing on growth stocks, emerging markets stocks, value stocks and more. You'll learn about hot new stocks and the market timing systems you need to profit from them. We work hard to help you make money! Get it today.

Report image

Enter Email Address:

We Value Your Privacy

Not interested or already a Cabot Wealth Advisory reader?
Click here to never see this message again.

Alexion Sees Growth From Competition-Free Drug

by on March 31, 2009
Alexion Pharmaceuticals (ALXN) has developed a new drug for a very rare disease and under the Orphan Drug Act, this drug will remain competition free for seven years, according to Investor's Business Daily.

The FDA approved Solaris for the treatment of the blood disease paroxysmal nocturnal hemoglobinuria or PNH in March 2007, IBD reported.

As the first drug approved for treatment of PNH, Solaris is guaranteed a rival-free market for seven years and beyond that, it has patent protection from generics, according to IBD. In 2008, Alexion was able to charge $389,000 in the U.S for a year of treatment with Solaris, which is largely paid for by health insurers.

This has contributed to strong growth and financial performance. In its fourth quarter, Alexion has revenue of just more than $77 million, up from just $24 million in the same period last year, IBD reported.

Editor Timothy Lutts recently wrote in Cabot Wealth Advisory about the excellent opportunity found in Alexion, which turned profitable in 2008 and is experiencing incredible growth.  Please read 5 Rules for Sucessful Growth Investing. 

 

Our Free Newsletter

Cabot Wealth Advisory delivers independent, no-nonsense investment advice on how to build long-lasting wealth. Learn about new hot stocks & the market timing indicators to profit from them. Simply enter your email address below - Start today!

We Value Your Privacy